Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 1

Interventions

pembrolizumab 37 Carboplatin 31 Cisplatin 30 Paclitaxel 23 Nivolumab 21 Pemetrexed 21 Dexamethasone 18 Gemcitabine 18 Ipilimumab 15 Docetaxel 13 Fluorouracil 13 Capecitabine 12 Rituximab 12 Cyclophosphamide 10 Cytarabine 10 Trastuzumab 9 atezolizumab 9 daratumumab 9 olaparib 9 130-nm albumin-bound paclitaxel 8 Lenalidomide 8 Prednisone 8 durvalumab 8 trastuzumab deruxtecan 8 Bevacizumab 7 Bortezomib 7 Fulvestrant 7 Oxaliplatin 7 Vinorelbine 7 cabozantinib 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Has announcements × melflufen × Clear all

NCT02963493 2022-11-22

HORIZON

Oncopeptides AB

Phase 2 Completed

157 enrolled 26 charts 1 FDA

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡